Globe Newswire

— AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs —

— AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content Creation —

TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- Today, during Computex 2024, AMD (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new... (continue reading...)

— Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities —

— New AMD Instinct MI325X accelerator expected to be available in Q4 2024 with up to 288GB of HBM3E memory; new AMD Instinct MI350 series accelerators based on AMD CDNA 4 architecture expected to be available in 2025 with 35x generational increase in AI inference performance —

TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- At... (continue reading...)

— Expanded AMD Instinct accelerator roadmap brings annual cadence of leadership AI accelerators; next generation AMD EPYC processors to extend data center CPU leadership —

— New AMD Ryzen AI 300 Series laptop and AMD Ryzen 9000 Series desktop processors deliver leading performance for Copilot+ PCs, gaming, content creation and productivity —

TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- Today at the Computex 2024 opening keynote, AMD (NASDAQ: AMD)... (continue reading...)

DUBAI, United Arab Emirates, June 02, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 3, 2024.

OKX Launches '100% Fee Rebate' Campaign

OKX today announced a '100% Fee Rebate' Campaign, which allows new customers to enjoy 100% trading fee rebates on their first five trades. This campaign is designed to help customers explore and access the digital financial markets with more ease and less cost.

... (continue reading...)

• Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)
• TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy
• Under the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply... (continue reading...)